Shuwen Biotech announces its winning of an outstanding award in the national finals for the 7th Annual Innovation and Entrepreneurship organized by Chinese Ministry of Science and Technology held on November 14. The 230 national finalists were selected from 3,667 biomedical enterprises from all across China through local and provincial competitions.

Shuwen Biotech, with its proprietary CapCord™ Preeclampsia Detection Kit, entered the national finals with the First Place Award in the city of Xuancheng and the First Place Award in biotechnology of Anhui Province.

Shuwen developed the CapCord™ Preeclampsia Detection Kit under a patent licensing and collaboration between Shuwen Biotech and Yale University. The non-invasive point of care test (POCT) is used in the prediction, screening, and diagnosis of preeclampsia and shows an accuracy rate of 95%.

Preeclampsia affects about 2.5-7% of all pregnant women and is the second leading cause of death among pregnant women all over the world. Shuwen’s CapCord™ Preeclampsia Detection Kit uses a non-invasive urine detection method, which is quick, effective, and shows results in 3 minutes. The product is protected by patents in many countries covering novel biomarkers, detection methods, and diagnostic devices. Shuwen Biotech expects to begin sales in the coming months.

The recognition in the competition highlights Shuwen’s outstanding ability to develop and commercialize innovative first-in-class diagnostic products.